Phase 2 Start
EXEL: Phase2_Start: A Phase 2, Single-Arm, Multicenter Trial of Zanzalintinib in Combination With Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer
December 15, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- December 15, 2026
- Company
- EXELIXIS, INC. (EXEL)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 2 Start
Phase2_Start: A Phase 2, Single-Arm, Multicenter Trial of Zanzalintinib in Combination With Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer
- Company
- EXELIXIS, INC. (EXEL)